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MaBACKGROUND In many cardiac units, aortic valve-sparing operations have become the preferred surgical procedure to
treat aortic root aneurysm in patients with Marfan syndrome, based on relatively short-term outcomes.
OBJECTIVES This study examined the long-term outcomes of aortic valve-sparing operations in patients with
Marfan syndrome.
METHODS All patients with Marfan syndrome operated on for aortic root aneurysm from 1988 through 2012 were
followed prospectively for a median of 10 years. Follow-up was 100% complete. Time-to-event analyses were calculated
using the Kaplan-Meier method with log-rank test for comparisons.
RESULTS A total of 146 patients with Marfan syndrome had aortic valve-sparing operations. Reimplantation of the
aortic valve was performed in 121 and remodeling of the aortic root was performed in 25 patients. Mean age was
35.7  11.4 years and two-thirds were men. Nine patients had acute, 2 had chronic type A, and 3 had chronic type B aortic
dissections before surgery. There were 1 operative and 6 late deaths, 5 caused by complications of dissections. Mortality
rate at 15 years was 6.8  2.9%, higher than the general population matched for age and sex. Five patients required
reoperation on the aortic valve: 2 for endocarditis and 3 for aortic insufﬁciency. Three patients developed severe, 4
moderate, and 3 mild-to-moderate aortic insufﬁciency. Rate of aortic insufﬁciency at 15 years was 7.9  3.3%, lower after
reimplantation than remodeling. Nine patients developed new distal aortic dissections during follow-up. Rate of
dissection at 15 years was 16.5  3.4%.
CONCLUSIONS Aortic valve-sparing operations in patients with Marfan syndrome were associated with low rates of
valve-related complications in long-term follow-up. Residual and new aortic dissections were the leading cause of death.
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ABBR EV I A T I ON S
AND ACRONYMS
AI = aortic insufﬁciency
MV = mitral valve
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1446Aortic valve-sparing operations have now
become the preferred surgical procedure in
our center to treat young patients with aortic
root aneurysm (5) and approximately one-
third of them had the diagnosis of Marfansyndrome according to Ghent criteria (6,7). This study
examines the long-term outcomes of aortic valve-
sparing operations in patients with Marfan syndrome.SEE PAGE 1454METHODS
STUDY POPULATION. From September 1988 through
December 2012, a total of 149 patients with the diag-
nosis of Marfan syndrome by Ghent criteria (6,7) were
operated on for aortic root aneurysm or Stanford type
A aortic dissection at Toronto General Hospital by 1
surgeon (T.E.D.). The original Ghent criteria (6) were
used retrospectively to identify patients operated on
before 1997, then prospectively from 1997 through
2010; the revised criteria have been used since then
(7). Three patients had aortic root replacement with a
conduit containing a mechanical valve because of
grossly abnormal aortic cusps and were excluded. The
remaining 146 patients had aortic valve-sparing op-
erations. This study was approved by the University
Health Network Research Ethics Board and patients’
consent was waived.
SURGICAL TECHNIQUES. Two types of aortic valve-
sparing operations were performed in these patients
(Figure 1): reimplantation of the aortic valve (the Da-
vid operation [1]) and remodeling of the aortic root
(the Yacoub operation [2]). Reimplantation of the
aortic valve was performed by detaching the coronary
arteries from the aneurysmal aortic sinuses, leaving a
small rim of tissue around their oriﬁces; a narrow rim
of aortic sinus tissue was also left attached to the
aortic annulus. Next, a tubular Dacron graft of
appropriate diameter was sutured on the outside of
the left ventricular outﬂow tract immediately below
the level of the nadir of the aortic annulus. The
remnants of aortic sinuses were sutured inside the
graft, recreating the crescent shape of the aortic
annulus. The cusps were examined to ensure that
their coaptation level was well above the level of the
nadir of the aortic annulus. If 1 or more aortic cusps
were prolapsing, their free margin was shortened by
plication along the nodule of Arantius. Additionally,
if large fenestrations were present on the free margin
along the commissural areas, a double layer of a
ﬁne expanded polytetraﬂuoroethylene suture was
weaved along the free margin of the cusp from
commissure to commissure. Finally, the coronaryarteries were reimplanted on the Dacron graft. During
the second decade of experience with this operation,
neoaortic sinuses were created by using a slightly
larger graft and reducing its diameter at the sub-
annular and sinotubular junction levels (Figure 1).
Remodeling of the aortic root was performed by
preparing the aortic root as described previously and
tailoring a tubular Dacron in such a way as to recreate
the aortic sinuses and suturing it to the remnants of
aortic sinuses and aortic annulus. If the aortic
annulus was deemed dilated at the time of surgery,
an external annuloplasty with a Dacron band along
the ﬁbrous components of the left ventricular outﬂow
tract was performed. The aortic cusps and coronary
arteries were handled similarly as with the reim-
plantation procedure.
FOLLOW-UP. All patients have been followed pro-
spectively with echocardiographic studies and peri-
odic computed tomography or cardiac magnetic
resonance imaging of the entire aorta every 3 to 5 years,
unless the patient had a history of aortic dissection or
another pre-existing aneurysm, in which case imaging
of the aorta was performed more often. Given that
aortic insufﬁciency (AI) was assessed by echocardiog-
raphy, we used the date of the ﬁrst post-operative
study to reveal AI greater than mild as the time of
event. Although the apparition of AI might predate the
echocardiogram, using the ﬁrst report of the abnor-
mality is an adequate and only available surrogate.
STATISTICAL ANALYSIS. Data are described as mean
SD (continuous variables) or frequencies (categorical
variables) as appropriate. Rates of mortality, reopera-
tions, AI, and aortic dissections were calculated using
the Kaplan-Meier method with log-rank test for
comparisons between groups. To account for the
concomitant probability of death or other adverse
event, competing risk analysis was used. In competing
risk analysis, at time zero, all patients were free
from adverse events; patients transiting to either
death or other adverse event, whichever occurred ﬁrst
and at the same time, were removed from the propor-
tion of patients who were alive and free from adverse
events. Sex-speciﬁc life tables from the Province of
Ontario from the 2000 to 2002 period (available from
Statistics Canada) were used to estimate predicted sur-
vival of the patient cohort with yearly estimates ﬁtted
with an exponential regression model. All statistical
analyses were performed using SAS statistical software
version 9.3 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
A total of 146 patients were included in this study.
Clinical follow-up was 100% complete to a median of
FIGURE 1 Aortic Valve-Sparing Operations
Reimplantation of the aortic valve is performed with a tubular graft or with tailored graft to recreate the aortic sinuses, whereas remodeling of
the aortic root was performed by tailoring a tubular Dacron in such a way as to recreate the aortic sinuses and suturing it to the remnants of
aortic sinuses and aortic annulus.
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144710.0 years (interquartile range: 3.6 to 14.0 years) and
echocardiographic follow-up was complete to a
median of 9.3 years (interquartile range: 3.2 to
13.4 years). Follow-up for this study was closed on
December 31, 2014.
Table 1 describes the pre-operative clinical,
echocardiographic, and angiographic data. Table 2
provides the surgical data. In addition to the aortic
valve-sparing operation, one-fourth of the patients
had other procedures, mitral valve (MV) repair being
the most common.
There was 1 operative death caused by an acute
type B aortic dissection and malperfusion on the day
after surgery. Ten patients required reopening of the
chest because of post-operative bleeding, pericardial
tamponade, or cardiac arrest. In 1 of these patients,
the right lobe of the liver was torn during resuscita-
tion and was successfully repaired. Transfusion of
homologous blood products (packed cells, fresh frozen
plasma, or platelets) was needed in 63 of 146 (43%)
patients. Seventeen patients developed transient
atrial ﬁbrillation and 1 patient required a permanent
transvenous pacemaker for sick sinus syndrome (this
patient had concomitant MV repair and the mazeprocedure for chronic atrial ﬁbrillation). There was
no other perioperative complication. Post-operatively,
patients were advised to take a beta-blocker or, if
not tolerated, an alternative antihypertensive agent.
LATE MORTALITY AND MORBIDITY. There were 6
late deaths: 4 caused by complications of aortic dis-
sections and 2 by complications of chronic obstruc-
tive pulmonary disease in patients with severe
kyphoscoliosis. The mortality rate ( SE) at 15 years
was 6.8  2.9% (Table 3). In the Kaplan-Meier analysis
of mortality rate over time, the study population was
compared with the general population of Ontario
matched for age and sex (Figure 2).
During follow-up, 1 patient with chronic aortic
dissection and intimal ﬂaps in the aortic arch suffered
a stroke with complete recovery; another patient with
infective endocarditis caused by Staphylococcus
aureus suffered an embolic stroke with partial
neurologic recovery. In addition, 5 patients suffered a
transient ischemic attack. Rate of thromboembolism
at 15 years was 4.1  2.0%.
Two patients developed infective endocarditis
with aortic root abscess both caused by S. aureus at
TABLE 1 Clinical and Echocardiographic Characteristics
(N ¼ 146)
Clinical data
Age at surgery, yrs 35.7  11.4
11–20 8 (5.4)
21–30 44 (30.1)
31–40 45 (30.8)
41–50 30 (20.5)
51–60 16 (10.9)
61–70 3 (2.0)
Male 99 (67.8)
Body surface area, m2 2.06  0.29
Body mass index, kg/m2 4.5  5.1
Chest wall deformity
Pectus excavatum 16 (11.0)
Pectus carinatum 14 (9.6)
Scoliosis/kyphoscoliosis 20 (13.7)
Ectopia lentis 64 (43.8)
Dura ectasia 47 (32.2)
Family history of Marfan syndrome 43 (29.6)
Family history of aortic dissection 23 (15.8)
Proven FB N1 mutation* 39 (26.7)
Acute type A dissection 9 (5.4)
Chronic type A dissection 2 (1.4)
Chronic type B dissection 3 (2.1)
New York Heart Association functional class
I 116 (80.0)
II 16 (11.0)
III 6 (4.1)
IV 8 (5.5)
Left ventricular ejection fraction, %
$60 122 (84.1)
40–59 22 (15.2)
20–39 1 (0.7)
Associated diseases
Diabetes mellitus 2 (1.4)
Hypertension 25 (17.1)
Hyperlipidemia 12 (8.2)
Smoking history 59 (40.7)
Previous stroke or transient ischemic attack 3 (2.1)
Chronic obstruction pulmonary disease 4 (2.7)
Peripheral vascular disease 2 (1.4)
Renal failure (hemodialysis) 1 (0.7)
History of infective endocarditis 3 (2.1)
Main indication for surgery
Presence of aortic root aneurysm 112 (76.7)
Acute/chronic type A aortic dissection 11 (7.5)
Severe aortic insufﬁciency 15 (10.2)
Severe mitral insufﬁciency þ aneurysm 8 (5.4)
Continued in the next column
TABLE 1 Continued
Echocardiographic/CT/CMR data
Aortic root diameter, mm 54  0.6
Aortic valve morphology
Tricuspid aortic valve 140 (96.6)
Bicuspid aortic valve 5 (3.4)
Aortic insufﬁciency (n ¼ 131)
None/trace 65 (49.6)
Mild 28 (21.4)
Moderate 20 (15.3)
Severe 18 (13.7)
Mitral regurgitation (moderate/severe) 21 (14.4)
Tricuspid regurgitation (moderate) 1 (0.7)
Atrial septal defect 10 (6.9)
Ventricular septal defect 2 (1.4)
Other
Coronary artery disease 7 (4.8)
Values are mean  SD or n (%). *Only patients operated on recently were tested.
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography.
TABLE 2 Surgical Data
Aortic valve-sparing operation 146 (100)
Reimplantation of the aortic valve 121 (82.9)
Remodeling of the aortic root 25 (17.1)
Graft diameter, mm 30.3  3.1
Graft diameter range, mm 24–34
Aortic cusps shortened
1 30 (20.6)
2 12 (8.2)
3 5 (3.4)
Aortic cusps reinforced with Gore-Tex
1 38 (26.0)
2 6 (4.1)
3 2 (1.4)
Creation of neoaortic sinuses
Reimplantation 51 (42)
Remodeling 25 (100)
Concomitant procedures
Aortic arch replacement 9 (6.2)
Repair of congenital heart defects 12 (8.2)
Mitral valve repair 21 (14.4)
Tricuspid valve repair 1 (0.7)
Maze procedure for atrial ﬁbrillation 1 (0.7)
Coronary artery bypass 7 (4.8)
Repair of abdominal aortic aneurysm 1 (0.7)
Other data
Cardiopulmonary bypass time, min 134  29
Range 72–210
Aortic clamping time, min 111  24
Range 93–246
Values are n (%) or mean  SD.
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144812 and 23 years after surgery. Both patients were
successfully treated with antibiotics and aortic root
replacement using an aortic valve homograft.
REOPERATIONS. Five patients required reoperation
on the reconstructed aortic root: the 2 patients
described previously for infective endocarditis and
3 for AI. The 2 patients with endocarditis had
aortic root replacement with aortic homograft andthe other 3 had aortic root replacement with a
Dacron conduit containing a mechanical valve. All
patients survived reoperation. Rate of reoperation
on the aortic root at 15 years was 4.9  2.5% (Table 3,
TABLE 3 Kaplan-Meier Estimates*
Time Rate of Death Rate of Reoperation Rate of Dissection Rate of AI
5 yrs 2.24  1.28 (3) 0.74  0.73 (1) 12.76  2.90 (18) 1.65  1.16 (2)
10 yrs 3.56  1.82 (4) 3.18  1.86 (3) 16.51  3.44 (21) 4.14  2.07 (4)
15 yrs 6.79  2.86 (6) 4.91  2.50 (4) 16.51  3.44 (21) 7.97  3.33 (6)
Values are mean  SE Kaplan-Meyer estimates (n events). *Rate of death (from Figure 2), rate of reoperation in
the aortic root (from Central Illustration), rate of aortic dissection (from Central Illustration), and rate of aortic
insufﬁciency (from Figure 3) at various time intervals. Rates of reoperations and dissections are adjusted for
patient attrition over time in competing risk analysis.
AI ¼ aortic insufﬁciency greater than mild.
FIGURE 2 Mortality Over Time
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In this Kaplan-Meier analysis, the study population (salmon line)
was compared with expected sex- and age-speciﬁc population
survival (blue line). Dotted lines are standard error.
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1449Central Illustration). Reoperations were more common
in patients who had the remodeling procedure
(reimplantation vs. remodeling; hazard ratio: 0.16;
95% conﬁdence interval: 0.01 to 0.54; log-rank
p ¼ 0.01). In addition to reoperations on the aortic
root, 7 patients had replacement of the entire thoracic
and abdominal aorta because of distal aortic aneu-
rysms: 1 died, 1 became paraplegic, and 5 did well.
The patient who suffered paraplegia developed aortic
root abscess years later. Two patients required MV
repair for new severe mitral regurgitation.
AI/DISSECTIONS. During the entire follow-up, 3
patients developed severe AI and underwent re-
operations. Another 4 developed moderate and 3
developed mild-to-moderate AI. The remaining 135
operative survivors had no, trace, or mild AI. Rate of
AI greater than mild at 15 years was 7.9  3.3%
(Table 3). Figure 3 shows the rate of AI greater than
mild in all patients and also according to the type of
aortic valve-sparing operation (reimplantation vs.
remodeling, hazard ratio: 0.43; 95% conﬁdence in-
terval: 0.10 to 1.03; log-rank p ¼ 0.08). Additionally, 2
patients developed severe aortic root abscess years
later. Two patients required MV repair for new severe
mitral (both underwent MV repair) and 9 developed
moderate aortic root abscess years later. Two patients
required MV repair for new severe mitral and
continue under surveillance.
Before aortic root surgery, 11 patients had Stanford
type A and 3 had type B aortic dissections. Post-
operatively, 9 patients developed new aortic dissec-
tions: 1 in the aortic arch at 8 years, and 8 type B at
Day 1 to 23 years after the aortic valve-sparing
operation. Two patients with type B aortic dissec-
tions died during the acute phase because of mal-
perfusion. Only 1 of the 9 patients with new
dissections was not on a beta-blocker or alternative
antihypertensive agent when the new aortic dissec-
tion occurred. Rate of all aortic dissections in the
competing risk analysis is shown in the Central
Illustration; the rate of aortic dissection at 15 years
was 16.5  3.4% (Table 3). In addition to aortic dis-
sections, 3 other patients developed chronic thoracic
or abdominal aneurysms.
DISCUSSION
Before the advent of open-heart surgery, the survival
of patients with Marfan syndrome was greatly
reduced because of aortic dissections or rupture of
the aorta (8). Replacement of the aortic root with a
conduit containing a valve (Bentall procedure [9])
improved that dismal prognosis. The Bentall proce-
dure is usually performed with a tubular Dacron graftcontaining a mechanical valve but it can also be done
with an aortic valve bioprosthesis or aortic homograft
(3). Replacement of the entire aortic root, including
the aortic valve cusps, was the standard treatment of
aortic root aneurysms until aortic valve-sparing op-
erations were developed (1,2).
This study examined the long-term outcomes of
aortic valve-sparing operations in adult patients with
Marfan syndrome. The number of adverse events was
relatively small, limiting the value of statistical ana-
lyses, but conﬁrms the safety and efﬁcacy of aortic
valve-sparing operations. Our operative mortality
was <1%; other surgeons have reported equally low
operative mortality after these operations (10–13).
Mortality at 15 years was 6.8%, slightly higher than the
general population matched for age and sex. However,
this mortality rate seems much lower than that re-
ported for patients treated with the Bentall procedure
(3,13). In a series of 271 patients with Marfan syndrome
from Johns Hopkins Hospital treated mostly with
Bentall procedures with mechanical valves, the mor-
tality rate at 15 years was approximately 24% (13). The
CENTRAL ILLUSTRATION Aortic Valve-Sparing in Marfan Syndrome: Reoperation and Aortic Dissection
A
B
N:       111         92          81          71          60         40         26          16           8    
N:      125        106        94         84          72          50         35          22          14
David, T.E. et al. J Am Coll Cardiol. 2015; 66(13):1445–53.
Competing risk analyses of reoperation (A) and aortic dissections (B) in the years after aortic valve-sparing operations also show patients alive
and free from or who experienced death without either reoperation or aortic dissection, respectively. Rates of reoperation or aortic dissection
and death without these procedures were obtained by Kaplan-Meier analysis, as was freedom from either event over time.
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FIGURE 3 Aortic Insufﬁciency
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Kaplan-Meier analysis shows rate of aortic insufﬁciency greater
than mild over time in all patients (A) and according to the type
of aortic valve-sparing operation (B). Dotted lines are standard
error.
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1451survival advantage in our series of aortic valve-sparing
operations is also evident compared with that from a
multicenter series of 675 patients with Marfan syn-
drome treated largely with Bentall operation (3).
Although the patient proﬁles may have been different
in those studies, the risk factors that are known to
affect late survival after cardiac surgery, such as age,
aortic dissections, mitral insufﬁciency, and coronary
artery disease, seem to be similar to ours. Only a ran-
domized clinical trial could determine unequivocally
whether there is indeed a survival beneﬁt associated
with aortic valve-sparing operations compared
with the Bentall procedure. However, such a trial is
unlikely to ever be conducted given that aortic
valve-sparing operations have already become the
preferred procedure in most centers.
Surgery for aortic root aneurysm in patients with
Marfan syndrome is recommended when the trans-
verse diameter of the aortic root reaches 50 mm or
even smaller (45 mm) when there is a family history
of aortic dissection or pregnancy is intended (14,15).
Patients with Marfan syndrome are usually in their
third or fourth decades of life when this surgery isrequired. Bioprosthetic aortic valves and aortic ho-
mografts are not durable in young adults (16,17).
Mechanical valves are durable, but require lifelong
anticoagulation with drugs like warfarin, which are
associated with a constant risk of bleeding and
thromboembolism (18). Thus, there is a preference for
aortic valve-sparing operations in young patients
because of their proven durability and lack of
requirement for anticoagulation. Pre-operative AI is
not a contraindication to an aortic valve-sparing
operation as long as the cusps are reasonably elastic
and the cusp prolapse is addressed during the pro-
cedure. Actually, more than one-half of our patients
needed 1 or more cusps repaired at the time of the
aortic valve-sparing procedure.
A review and meta-analysis by Benedetto et al. (19)
compared 972 patients with Marfan syndrome who
had undergone the Bentall procedure with 413 who
had undergone aortic valve-sparing operations. Dur-
ing a relatively short duration of follow-up, they
found that the probability of reoperation was 4 times
higher after the aortic valve-sparing operation than
after the Bentall procedure (1.3%/year vs. 0.3%/year).
However, risk of thromboembolism after the aortic
valve-sparing operation was lower than after the
Bentall procedure (0.3%/year vs. 0.7%/year), whereas
the composite risk of reoperation, thromboembolism,
and bleeding was similar. The authors concluded
that aortic valve-sparing operations represent a
valuable option, but should be used with caution in
patients for whom the durability of the repair was
questionable.
A recent report from a prospective, international car-
diac surgery registry comparing 239 aortic valve-sparing
operations with 77 Bentall procedures in patients with
Marfan syndrome showed similar survival at 1 year,
but after aortic valve-sparing operations, 7% had AI
of at least moderate severity and 1 patient required
aortic valve reoperation for valve failure (20). Such a
high 1-year post-operative failure rate is worrisome
and contrasts with our ﬁndings, perhaps emphasizing
the need for centralizing care for patients with
Marfan syndrome. In centers having a large experience
with this type of surgery, such as Cleveland Clinic,
Johns Hopkins Hospital, and Stanford University, the
freedom from reoperation is reportedly above 90% at
10 years (10–12).
In our experience, the rate of AI greater than mild
was approximately 8% at 15 years and the rate of
reoperation on the aortic root was even lower at just
under 5% (Central illustration). We were unable to
identify predictors of failure, likely because of the
sample size and small number of adverse events.
However, reimplantation of the aortic valve was
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the aortic root in our series and in a previous meta-
analysis (19). We believe that remodeling of the
aortic root is inappropriate for patients with Marfan
syndrome because the aortic annulus can dilate years
after the operation and cause AI (21). An external
annuloplasty band along the ﬁbrous components of
the left ventricular outﬂow tract was added in some
patients as illustrated in Figure 1, but our experience
is inadequate to draw conclusions on its effectiveness
in preventing annular dilation.
Common in patients with Marfan syndrome, chest
wall deformities can make the aortic root operation
difﬁcult. We have never added correction of the chest
wall deformity during aortic valve-sparing operations
but we have had to do the operation through a left
anterior thoracotomy in 2 patients because of severe
pectus excavatum.
In patients with Marfan syndrome, aortic root
involvement is the principal cause of death because
of proximal aortic dissections and rupture (15).
Replacement of the aortic root and ascending aorta
prevents proximal aortic dissections and increases
the lifespan of patients with Marfan syndrome (13).
Aortic valve-sparing operations may further increase
longevity, but late survival is shorter than in the
general population, largely because of complications
of residual dissections and development of new ones
in the remaining aorta. The recognition of this prob-
lem is not new (22,23). A recent observational study
by den Hartog et al. (23) on 600 patients with Marfan
syndrome from a Dutch registry examined the issue
of distal aortic dissections. They excluded patients
who had previous aortic dissections but included
194 patients who had prophylactic aortic root surgery,
either before or during the median observation time
of 6 years. Distal aortic dissections occurred in 54
patients for an annualized rate of 1.5%. Multivariate
analysis identiﬁed previous aortic root surgery and a
descending thoracic aorta diameter cut-off of $27 mm
as independent predictors of distal dissections.
However, only 53% of the distal dissections occurred
in aortas with diameters $27 mm. The authors spec-
ulated that replacement of the ascending aorta with a
noncompliant Dacron graft may result in higher pul-
satile forces on the aortic arch and proximal
descending thoracic aorta, increasing the risk of
dissection. Most patients (73%) were taking a beta-
blocker and the remainder were on another antihy-
pertensive agent at the time of the dissection. The
study suggested no solution to the problem of distal
aortic dissections, but the ﬁndings emphasize the
importance of monitoring the distal aorta in all pa-
tients with Marfan syndrome, particularly those withprior aortic root surgery or dissections, with periodic
cardiac magnetic resonance imaging or computed
tomography imaging of the entire aorta in specialized
centers.
For more than 20 years, beta-blocker therapy has
been the mainstay of medical care for Marfan syn-
drome, based on the trial reported by Shores et al.
(24). Since 2006, when Habashi et al. (25) ﬁrst re-
ported that aortic aneurysm in a mouse model of
Marfan syndrome can be prevented by the antago-
nism of increased transforming growth factor-beta
signaling afforded by losartan, a number of human
clinical drug trials have been performed. In adult
patients with Marfan syndrome, Groenink et al. (26)
demonstrated that losartan reduced the rates of pre-
operative aortic root dilation and post-operative
aortic arch dilation compared with placebo. Lacro
et al. (27) found no signiﬁcant difference in the rate of
aortic root dilation in children and young adults with
Marfan syndrome treated with losartan compared
with atenolol. Therefore, it seems that the ongoing
improvement in life expectancy for patients with
Marfan syndrome remains primarily caused by the
increased frequency of early diagnosis, more effective
monitoring, and elective aortic root aneurysm repair.
STUDY LIMITATIONS. This prospective observational
study has limitations largely because of its sample
size and the relatively small number of adverse
events. Early on the issue of annular dilation was not
recognized and it is possible that some failures were
related to the wrong technique of aortic valve-sparing
operation. In addition, one surgeon performed all
procedures, and the results may not be generalized.
CONCLUSIONS
Aortic valve-sparing operations, particularly the reim-
plantation procedure, are attractive and durable choices
to treat young adults with aortic root aneurysm associ-
ated with Marfan syndrome. This type of surgery is
complex and should be performed in centers with a high
volume of aortic root surgery and experience with aortic
valve repair. In addition, patients with Marfan syn-
drome must be followed throughout their lifetime by a
multidisciplinary group of professionals including car-
diologists, cardiac surgeons, and geneticists with pro-
tocols targeted at detecting distal aortic complications.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Aortic
valve-sparing operations to treat aortic root aneu-
rysm in patients with Marfan syndrome at a center
of excellence were associated with low rates of
valve-related complications during the ﬁrst 15 years
of observation, during which aortic dissection was
the leading cause of death. Repair of aortic root
aneurysms in these patients reduced the risk of
rupture of the replaced segment of the aorta and
valve-related adverse events, but did not prevent
distal aortic dissection.
TRANSLATIONAL OUTLOOK: More research is
needed to delineate the clinical factors and molecular
mechanisms responsible for aortic dissection in patients
with aortic disease associated with Marfan syndrome.
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